Potentiation of platelet responsiveness to nitric oxide by angiotensin-(1–7) is associated with suppression of superoxide release
- 1 January 2007
- journal article
- Published by Taylor & Francis in Platelets
- Vol. 18 (2), 158-164
- https://doi.org/10.1080/09537100600936158
Abstract
Recently we showed that angiotensin (Ang) II potentiates platelet aggregation, while Ang-(1-7) potentiates the anti-aggregatory action of the nitric oxide (NO) donor sodium nitroprusside (SNP), and may therefore counteract platelet NO resistance that accompanies cardiovascular disease and is associated with increased levels of superoxide (O(2)(-)). In the current study, we investigated whether the effect of Ang-(1-7) on platelet NO responsiveness is associated with the modulation of O(2)(-) release and is mediated by a specific Ang-(1-7) receptor. In whole blood, SNP (10 micromol/L) inhibited ADP (2.5 micromol/L)-induced platelet aggregation by 21 +/- 8% (p < 0.02), measured via extent of aggregation. Ang-(1-7) did not directly affect platelet aggregation, but potentiated the inhibitory action of SNP. This effect of Ang-(1-7) was bimodal, with maximal increase in SNP-induced inhibition of aggregation by incremental 18 +/- 2% (2-fold, on average; p<0.01) at 10-100 nmol/L Ang-(1-7) (Cmax), and was abolished at higher concentrations of Ang-(1-7). The Ang-(1-7) receptor antagonist D-ala7-Ang-(1-7) (1 micromol/L) completely eliminated the potentiating effects of Ang-(1-7). Platelet aggregation was accompanied by O(2)(-) release (assessed via lucigenin-derived chemiluminescence). SNP suppressed this O(2)(-) release, and Ang-(1-7) at Cmax augmented (by incremental 23 +/- 8%, p<0.03) the effect of SNP. In order to examine possible association of Ang-(1-7) receptor with platelets, we performed aggregation experiments in platelet-rich plasma. However, in these experiments Ang-(1-7) did not potentiate the anti-aggregatory action of SNP. Furthermore, in isolated polymorphonuclear leukocytes (PMN), a major cellular source of O(2)(-) in blood, Ang-(1-7) did not modify O(2)(-) release (after stimulation with fMLP, PMA or ADP), either in the absence or presence of SNP. Hence, Ang-(1-7) effects occurred only in whole blood. In conclusion, Ang-(1-7) potentiates the anti-aggregatory effects of NO donor, presumably via a specific Ang-(1-7) receptor. This potentiation is associated with the suppression of O(2)(-) release during aggregation and arises via an interaction between platelets and PMN.Sharmalar Rajendran; Yuliy Y. Chirkov; John D. HorowitKeywords
This publication has 27 references indexed in Scilit:
- The discovery of nitric oxide and its role in vascular biologyBritish Journal of Pharmacology, 2006
- Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activationJournal of Leukocyte Biology, 2005
- Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart diseaseJournal of Human Hypertension, 2004
- Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunctionThe American Journal of Cardiology, 2004
- Platelet activation during angiotensin II infusion in healthy volunteersBlood Coagulation & Fibrinolysis, 2000
- Synergistic effect of angiotensin-(1–7) on bradykinin arteriolar dilation in vivoPeptides, 1999
- Antiproliferative Actions of Angiotensin-(1-7) in Vascular Smooth MuscleHypertension, 1999
- Angiotensin-(1–7) Is a Modulator of the Human Renin-Angiotensin SystemHypertension, 1999
- Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric OxideHypertension, 1996
- Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension.Hypertension, 1993